ImmunityBio, Inc.
IBRX Nasdaq· Biological Products, (No Diagnostic Substances)
Last close · Oct 26, 2026
$7.81
KIRA · Stoqly’s AI analyst, in plain words
- ImmunityBio, Inc. had $113M of revenue in fiscal 2025, up 668.3% on the year before. Over five years, revenue changed +184.8% a year on average.
- Its operating margin was −226.0%, up 2,108.2 pts: of every 100 in sales, about −226 is left after running the business.
- ImmunityBio, Inc. lost $351M in fiscal 2025.
- Free cash flow was −$309M in fiscal 2025, −272.6% of revenue.
- ImmunityBio, Inc. has $241M more cash than debt.
Market cap
$8.2B
P/E
—
Revenue
$113M
Net income
−$351M
Free cash flow
−$309M
Operating margin
−226.0%
ImmunityBio, Inc. in 30 seconds · fiscal 2025
Are sales growing?
+668.3%
Yes. Sales grew 668.3% last year.
Does it make a profit?
−310.2%
No. It lost money last year.
Does profit turn into cash?
−272.6%
No. It spent more cash than it brought in.
How healthy are the accounts?
4 / 9
Mixed. It passes 4 of 9 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What ImmunityBio, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 23, 2026
- Legal name
- ImmunityBio, Inc.
- CIK
- 0001326110
ImmunityBio, Inc. · IBRX
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $0.9M | $0.2M | $0.6M | $14.7M | $113M |
| Revenue growth | 54.4% | −74.3% | 159.2% | 2,270.6% | 668.3% |
| Gross margin | — | 100.0% | 100.0% | 100.0% | 99.3% |
| Operating margin | −35,361.9% | −146,374.2% | −58,239.5% | −2,334.2% | −226.0% |
| Net income | −$347M | −$417M | −$583M | −$414M | −$351M |
| Net margin | −37,129.6% | −173,569.6% | −93,761.4% | −2,804.8% | −310.2% |
| Diluted EPS | −$0.89 | −$1.04 | −$1.15 | −$0.62 | −$0.38 |
| Cash | |||||
| Cash from operations | −$274M | −$338M | −$367M | −$391M | −$305M |
| Capital expenditure | $33.6M | $78.2M | $30.6M | $6.9M | $3.8M |
| Free cash flow | −$308M | −$416M | −$397M | −$398M | −$309M |
| FCF margin | −32,974.5% | −173,196.3% | −63,881.2% | −2,700.1% | −272.6% |
| Share buybacks | $0.0M | — | — | — | — |
| Share count change | 3.2% | 2.7% | 27.2% | 37.7% | 31.3% |
| Debt and strength | |||||
| Cash and short-term investments | $317M | $107M | $266M | $150M | $243M |
| Debt incl. finance leases | — | — | — | $1.2M | $2.0M |
| Shareholders' equity | −$242M | −$447M | −$587M | −$489M | −$500M |
| Current ratio | 0.9x | 0.3x | 5.0x | 3.4x | 5.1x |
| Interest coverage | −22.2x | −5.5x | −2.8x | −3.0x | −4.2x |
| Returns and quality | |||||
| Piotroski F-score | 2 | 1 | 3 | 3 | 4 |
| Altman Z'' | −19.2 | −35.0 | −21.5 | −33.1 | −24.9 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$9.5M
3 insiders
Of sales under plans
100%
$9.5M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
ImmunityBio, Inc. · IBRX
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $7.81 a share, the company is worth $8.2B.
Source: SEC EDGAR XBRL filings (CIK 0001326110). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.